Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma

Ann Sosa, Julie; Elisei, Rossella; Jarząb, Barbara; Balkissoon, Jai; Lu, S.; Bal, Chandrasekhar; Marur, Shanthi; W. Gramza, Ann; Ben Yosef, R.; J. Gitlitz, Barbara; R. Haugen, Bryan; G. Ondrey, Frank; Lu, Charles; M. Karandikar, S.; R. Khuri, Fadlo; Licitra, Lisa; C. Remick, Scot

doi:10.1089/thy.2013.0078

Public

Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma

Published in Thyroid • May 30, 2013

Authors:

Julie Ann Sosa

Rossella Elisei

Barbara Jarząb

Abstract

BACKGROUND: Anaplastic thyroid cancer (ATC), a rare highly vascularized tumor, has a dismal outcome. We conducted an open-label study of doublet carboplatin/paclitaxel chemotherapy with or without fosbretabulin in patients with ATC. METHODS: Patients were randomly assigned in a 2:1 ratio to 6 cycles...

Subject

Medicine

Carboplatin

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!